Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis

Annals of Pharmacotherapy

Volumn 48, Issue 12, 2014, Pages 1611-1619

  Covvey, Jordan R ^a   Mancl, Erin E ^b  

^a DUQUESNE UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

cryptogenic fibrosing alveolitis; idiopathic pulmonary fibrosis; N acetylcysteine; nintedanib; pharmacotherapy; pirfenidone; usual interstitial pneumonia

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; ENDOTHELIN RECEPTOR ANTAGONIST; NINTEDANIB; PIRFENIDONE; PLACEBO; PREDNISONE; ANTIINFLAMMATORY AGENT; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULANT THERAPY; CLINICAL FEATURE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UNITED STATES; IDIOPATHIC PULMONARY FIBROSIS;

ACETYLCYSTEINE; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PREDNISONE; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921457684     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014551015     Document Type: Review

References (53)

1. Raghu G,Collard HR,Egan JJ, et al.An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.Am J Respir Crit Care Med. 2011;183:788-824
2. Nalysnyk L,Cid-Ruzafa J,Rotella P,Esser D.Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.Eur Respir Rev. 2012;21:355-361
3. Ley B,Collard HR.Epidemiology of idiopathic pulmonary fibrosis.Clin Epidemiol. 2013;5:483-492
4. Olson AL,Swigris JJ,Lezotte DC,Norris JM,Wilson CG,Brown KK.Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003.Am J Respir Crit Care. Med. 2007;176:277-284
5. Hansell DM,Bankier AA,MacMahon H,McLoud TC,Müller NL,Remy J.Fleischner Society: glossary of terms for thoracic imaging.Radiology. 2008;246:697-722
6. Selman M,King TE,Pardo A.Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med. 2001;134:136-151
7. Baumgartner KB,Samet JM,Stidley CA,Colby TV,Waldron JA.Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 1997;155:242-248
8. Tang YW,Johnson JE,Browning PJ, et al.Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis.J Clin Microbiol. 2003;41:2633-2640
9. Meliconi R,Andreone P,Fasano L, et al.Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis.Thorax. 1996;51:315-317
10. Stewart JP,Egan JJ,Ross AJ, et al.The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 1999;159 (4, pt 1): 1336-1341
11. Hubbard R,Lewis S,Richards K,Johnston I,Britton J.Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.Lancet. 1996;347 (8997): 284-289
12. Lawson WE,Loyd JE.The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease?.Proc Am Thorac Soc. 2006;3:345-349
13. Kim DS,Collard HR,King TE.Classification and natural history of the idiopathic interstitial pneumonias.Proc Am Thorac Soc. 2006;3:285-292
14. Patel NM,Lederer DJ,Borczuk AC,Kawut SM.Pulmonary hypertension in idiopathic pulmonary fibrosis.Chest. 2007;132:998-1006
15. Cantin AM,North SL,Fells GA,Hubbard RC,Crystal RG.Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis.J Clin Invest. 1987;79:1665-1673
16. Cantin AM,Hubbard RC,Crystal RG.Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis.Am Rev Respir Dis. 1989;139:370-372
17. Meyer A,Buhl R,Magnussen H.The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis.Eur Respir J. 1994;7:431-436
18. Meyer A,Buhl R,Kampf S,Magnussen H.Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals.Am J Respir Crit Care Med. 1995;152:1055-1060
19. Behr J,Maier K,Degenkolb B,Krombach F,Vogelmeier C.Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression.Am J Respir Crit Care Med. 1997;156:1897-1901
20. Demedts M,Behr J,Buhl R, et al.High-dose acetylcysteine in idiopathic pulmonary fibrosis.N Engl J Med. 2005;353:2229-2242
21. Am J Respir Crit Care Med. 2000;161 (2): 646-664
22. Raghu G,Anstrom KJ,King TE,Lasky JA,Martinez FJ.Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.N Engl J Med. 2012;366:1968-1977
23. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.N Engl J Med. 2014;370:2093-2101
24. Swigris JJ,Brown KK.The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis.BioDrugs. 2010;24:49-54
25. du Bois RM.Blocking endothelin: breaking new ground.Eur Respir Rev. 2007;16:24-29
26. King TE,Behr J,Brown KK, et al.BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2008;177:75-81
27. King TE,Brown KK,Raghu G, et al.BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2011;184:92-99
28. Raghu G,Behr J,Brown KK, et al.Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.Ann Intern Med. 2013;158:641-649
29. Raghu G,Million-Rousseau R,Morganti A,Perchenet L,Behr J.Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.Eur Respir J. 2013;42:1622-1632
30. Günther A,Mosavi P,Ruppert C, et al.Enhanced tissue factor pathway and fibrin turnover in the alveolar component of patients with interstitial lung disease.Thromb Haemost. 2000;83:853-860
31. Kobayashi H,Gabazza EC,Taguchi O, et al.Protein C anticoagulant system in patients with interstitial lung disease.Am J Respir Crit Care Med. 1998;157 (6, pt 1): 1850-1854
32. Imokawa S,Sato A,Hayakawa H,Kotani M,Urano T,Takada A.Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis.Am J Respir Crit Care Med. 1997;156 (2): 631-636
33. Hubbard RB,Smith C,Le Jeune I,Gribbin J,Fogarty AW.The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study.Am J Respir Crit Care Med. 2008;178:1257-1261
34. Sode BF,Dahl M,Nielsen SF,Nordestgaard BG.Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study.Am J Respir Crit Care Med. 2010;181:1085-1092
35. Sprunger DB,Olson AL,Huie TJ, et al.Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.Eur Respir J. 2012;39:125-132
36. Kubo H,Nakayama K,Yanai M, et al.Anticoagulant therapy for idiopathic pulmonary fibrosis.Chest. 2005;128:1475-1482
37. Noth I,Anstrom KJ,Calvert SB, et al.A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2012;186:88-95
38. Potts J,Yogaratnam D.Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.Ann Pharmacother. 2013;47:361-367
39. Taniguchi H,Ebina M,Kondoh Y, et al.Pirfenidone in idiopathic pulmonary fibrosis.Eur Respir J. 2010;35:821-829
40. Noble PW,Albera C,Bradford WZ, et al.Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.Lancet. 2011;377:1760-1769
41. InterMune. Esbriet® (pirfenidone). http://www.intermune.com/pirfenidone. Accessed September 2, 2014.
42. King TE,Bradford WZ,Castro-Bernardini S, et al.A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.N Engl J Med. 2014;370:2083-2092
43. Electronic Medicines Compendium. Esbriet 267 mg hard capsules (summary of product characteristics). http://www.medicines.org.uk/emc/medicine/26942/SPC/Esbriet+267+mg+hard+capsules/. Accessed July 30, 2014.
44. Allen JT,Spiteri MA.Growth factors in idiopathic pulmonary fibrosis: relative roles.Respir Res. 2002;3:13
45. Daniels CE,Lasky JA,Limper AH, et al.Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results.Am J Respir Crit Care Med. 2010;181:604-610
46. Richeldi L,Costabel U,Selman M, et al.Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.N Engl J Med. 2011;365:1079-1087
47. Richeldi L,du Bois RM,Raghu G, et al.Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N Engl J Med. 2014;370:2071-2082
48. Boehringer Ingelheim. EMA accepts marketing authorisation application for nintedanib in IPF. http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/05_june_2014_ipf.html. Accessed June 9, 2014.
49. Boehringer Ingelheim. U.S. FDA accepts NDA filing for Boehringer Ingelheim’s investigational nintedanib and grants priority review designation for the treatment of idiopathic pulmonary fibrosis. http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/07-02-14-us-fda-accepts-nda-filing-boehringer-ingelheims-investigational-nintedanib-grants-priority-review-designation-treatment-idi-opathic-pulmonary-fibrosis.html. Accessed July 4, 2014.
50. Richeldi L,Davies HR,Ferrara G,Franco F.Corticosteroids for idiopathic pulmonary fibrosis.Cochrane Database Syst Rev. 2003; (3):
51. Spagnolo P,Del Giovane C,Luppi F, et al.Non-steroid agents for idiopathic pulmonary fibrosis.Cochrane Database Syst Rev. 2010; (9):
52. Food and Drug Administration (FDA). PIRFENIDONE capsules: NDA 22-535. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ucm203083.pdf. Accessed July 30, 2014.
53. Lee JS,McLaughlin S,Collard HR.Comprehensive care of the patient with idiopathic pulmonary fibrosis.Curr Opin Pulm Med. 2011;17:348-354